Agmatine and Agmatine Analogs in the Treatment of Epilepsy, Seizure, and Electroconvulsive Disorders

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 1240 days. See application ?le for complete search history. Magdalena Sastre et al., " Metabolism of agmatine in macrophages.' modulation by lipopolysaccharide and inhibitory cytokines " , S. Regunathan et al., " Agmatine (decarboxylated arginine) is sysnthesized and stored in astrocytes " , Rapid Science Publishers, Elena Galea et al., " Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine " , Biochem. (57) ABSTRACT Pharmaceutical preparations containing of agmatine, conge ners, analogs or derivatives thereof for use in preventing or treating epilepsy, seizures and other electroconvulsive disor ders are provided. Embodiments include administering an effective amount of agmatine, an agmatine analog or a phar maceutically acceptable salt thereof to a human subject in need of treatment or prevention of epilepsy, seizure or other electroconvulsive disorder to treat, reduce, or prevent the disorder in the subject. The early identi?cation of anticonvulsant activity.' role of the maximal electroshock and subcutaneous pentylenetetrazol seizure models " , ELECTROCONVULSIVE DISORDERS " the entire disclo sure of Which is incorporated herein by reference. The present invention relates to the use of agmatine and analogs thereof in the prevention and treatment of epilep sies, seizures, and other electroconvulsive disorders.